This morning, Merck announced that a clinical trial had failed...

This morning, Merck announced that a clinical trial had failed to show that giving its HIV drug Isentress once-a-day was as effective as the current twice-a-day dosing schedule. That exposes Isentress, one of Mercks top sellers, to competition from similar, once daily pills in development by Gilead Sciences and GlaxoSmithKline (Ed. and AVEXA).

Merck will still make plenty of money on Isentress. On sale since 2006, Isentress could bring in $2 billion a year by 2015, according to analyst at J.P. Morgan, although todays news could mean that growth will slump thereafter.

http://blogs.forbes.com/matthewherper/2010/11/29/an-innovators-dilemma-for-merck-aids-drug/?boxes=businesschannelsections